Oritavancin in vitro activity against Gram-positive organisms from European medical centers: a 10-year longitudinal overview from the SENTRY Antimicrobial Surveillance Program (2010–2019)

References

• Fuhrmeister AS, Jones RN. The importance of antimicrobial resistance monitoring worldwide and the origins of SENTRY Antimicrobial Surveillance Program. Open Forum Infect Dis. 2019;6(Suppl 1):S1–S4. doi: 10.1093/ofid/ofy346.
   PubMedGoogle Scholar
• Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–655. doi: 10.1016/S0140-6736(21)02724-0.
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Fuhrmeister AS, et al. Antimicrobial resistance surveillance and new drug development. Open Forum Infect Dis. 2019;6:S5–S13. doi: 10.1093/ofid/ofy345.
   PubMed Web of Science ®Google Scholar
• Arhin FF, Moeck G, Draghi DC, et al. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against gram-positive organisms from Europe: 2005-2008. Int J Antimicrob Agents. 2010;36:474–476. doi: 10.1016/j.ijantimicag.2010.07.010.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Pfaller MA, Shortridge D, et al. Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program. Open Forum Infect Dis. 2019;6:S47–S53. doi: 10.1093/ofid/ofy270.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Castanheira M, et al. Distribution of main gram-positive pathogens causing bloodstream infections in the United States and European hospitals during the SENTRY antimicrobial surveillance program (2010-2016): concomitant analysis of oritavancin in vitro activity. J Chemother. 2018;30:280–289. doi: 10.1080/1120009X.2018.1516272.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Sader HS, Flamm RK, et al. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY antimicrobial surveillance program for 2010-2014. Diagn Microbiol Infect Dis. 2018;91:199–204. doi: 10.1016/j.diagmicrobio.2018.01.029.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Cormican M, Flamm RK, et al. Temporal and geographic variation in antimicrobial susceptibility and resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-2016. Open Forum Infect Dis. 2019;6:S54–S62. doi: 10.1093/ofid/ofy344.
   PubMed Web of Science ®Google Scholar
• Sader HS, Mendes RE, Le J, et al. Antimicrobial susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific region: results from 20 years of the SENTRY antimicrobial surveillance program (1997-2016). Open Forum Infect Dis. 2019;6:S14–S23. doi: 10.1093/ofid/ofy263.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Arhin FF, Moeck G, et al. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014. Int J Antimicrob Agents. 2015;46:674–681. doi: 10.1016/j.ijantimicag.2015.08.014.
   PubMed Web of Science ®Google Scholar
• Huycke MM, Sahm DF, Gilmore MS. Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future. Emerg Infect Dis. 1998;4:239–249. doi: 10.3201/eid0402.980211.
   PubMed Web of Science ®Google Scholar
• Klinker KP, Borgert SJ. Beyond vancomycin: the tail of the lipoglycopeptides. Clin Ther. 2015;37:2619–2636. doi: 10.1016/j.clinthera.2015.11.007.
   PubMed Web of Science ®Google Scholar
• Munita JM, Bayer AS, Arias CA. Evolving resistance among gram-positive pathogens. Clin Infect Dis. 2015;61:S48–S57. doi: 10.1093/cid/civ523.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Metcalf BJ, Knipe KM, et al. vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio. 2014;5:e01386–e01414. doi: 10.1128/mBio.01386-14.
   PubMed Web of Science ®Google Scholar
• Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28:603–661. doi: 10.1128/CMR.00134-14.
   PubMed Web of Science ®Google Scholar
• Tavernier S, Sass A, De Bruyne M, et al. Decreased susceptibility of Streptococcus anginosus to vancomycin in a multispecies biofilm is due to increased thickness of the cell wall. J Antimicrob Chemother. 2018;73:2323–2330. doi: 10.1093/jac/dky216.
   PubMed Web of Science ®Google Scholar
• Brade KD, Rybak JM, Rybak MJ. Oritavancin: a new lipoglycopeptide antibiotic in the treatment of gram-positive infections. Infect Dis Ther. 2016;5(1):1–15. doi: 10.1007/s40121-016-0103-4.
   PubMed Web of Science ®Google Scholar
• Crotty MP, Krekel T, Burnham CA, et al. New gram-positive agents: the next generation of oxazolidinones and lipoglycopeptides. J Clin Microbiol. 2016;54(9):2225–2232. doi: 10.1128/JCM.03395-15.
   PubMed Web of Science ®Google Scholar
• Karaoui LR, El-Lababidi R, Chahine EB. Oritavancin: an investigational lipoglycopeptide antibiotic. Am J Health Syst Pharm. 2013;70(1):23–33. doi: 10.2146/ajhp110572.
   PubMed Web of Science ®Google Scholar
• Koomanachai P, Crandon JL, Nicolau DP. Newer developments in the treatment of gram-positive infections. Expert Opin Pharmacother. 2009;10(17):2829–2843. doi: 10.1517/14656560903357491.
   PubMed Web of Science ®Google Scholar
• WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; [accessed 2019 May]. Available from: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf
   Google Scholar
• Corey GR, Kabler H, Mehra P, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180–2190. doi: 10.1056/NEJMoa1310422.
   PubMed Web of Science ®Google Scholar
• Corey GR, Good S, Jiang H, et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254–262. doi: 10.1093/cid/ciu778.
   PubMed Web of Science ®Google Scholar
• USFDA. KIMYRSATM package insert. 2021 Mar. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214155s000lbl.pdf
   Google Scholar
• Duncan LR, Sader HS, Flamm RK, et al. Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014). Diagn Microbiol Infect Dis. 2016;86(3):303–306. doi: 10.1016/j.diagmicrobio.2016.07.025.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Walkty AJ, Baxter MR, et al. In vitro activity of oritavancin against gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013. Diagn Microbiol Infect Dis. 2014;80(4):311–315. doi: 10.1016/j.diagmicrobio.2014.09.003.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Flamm RK, et al. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother. 2014;58(5):2921–2924. doi: 10.1128/AAC.02482-13.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, et al. Activity of oritavancin against gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). J Antimicrob Chemother. 2015;70(2):498–504. doi: 10.1093/jac/dku421.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Castanheira M, Farrell DJ, et al. Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. J Antimicrob Chemother. 2016;71(12):3453–3458. doi: 10.1093/jac/dkw319.
   PubMed Web of Science ®Google Scholar
• Morrissey I, Seifert H, Canton R, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from Western European countries in 2011. J Antimicrob Chemother. 2013;68(1):164–167. doi: 10.1093/jac/dks344.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. M07ED11 methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 11th ed. Wayne (PA): CLSI; 2018.
   Google Scholar
• Clinical and Laboratory Standards Institute. M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement. Wayne (PA): CLSI; 2021.
   Google Scholar
• EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0; [2022 Jan; accessed 2022 Jan]. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi: 10.1111/j.1469-0691.2011.03570.x.
   PubMed Web of Science ®Google Scholar